Blog
Compounding must not become a drug-approval shortcut for Big Wellness
By Philip J. Schneider and Ronald P. Jordan Patients deserve innovation, but they also deserve evidence. FDA should not allow pharmacy compound-ing to become a shortcut around safety and efficacy standards that protect the public. If compounding becomes an entry point for every substance that...
Retatrutide 101: What Consumers Should Know About the Growing Online Market
Interest in next-generation obesity medicines is accelerating rapidly — and so is the online marketplace claiming to sell them. One of the latest examples is retatrutide, an investigational therapy currently being studied in clinical trials but increasingly promoted online through wellness...
5 Things to Know About the FDA’s Peptide Reversal
Author(s)Habiba Atta Fact checked by: Laura Joszt, MA FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist. When a reconstituted FDA advisory panel voted in late July to recommend 6 peptides for legal...
National Consumers League Commends FDA for Swift Action Against Hims & Hers
Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 Washington, DC – You can fool some of the people some of the time and all of the people some of the time. But you can’t fool all of the people all the time. On Friday, February 6, the Food and Drug Administration...
Receive News Alerts
Sign up to get the latest updates straight to your inbox.
The Alliance for Safe Biologic Medicines (ASBM) is a diverse coalition of stakeholders, including physicians, pharmacists, patient advocates, researchers, and biopharmaceutical manufacturers. Since 2010, ASBM has worked with regulators worldwide to shape policies that reflect the best interests of patients, ensuring access to lifesaving and life-enhancing medicines while fostering innovation in healthcare.